ReviewChinese medicine2026
Medicine-food homologous bioactives in metabolic dysregulation-associated osteoporosis: a review of preclinical evidence and potential liver-bone and gut-bone actions.
Review in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOsteoporosis is increasingly linked to metabolic dysregulation. Medicine-food homologous (MFH) materials contain diverse natural bioactives with reported osteoprotective effects, but their overall evidence landscape remains insufficiently integrated. PURPOSE: To synthesize preclinical evidence on MFH-derived bioactives that improve osteoporosis-related phenotypes and to discuss their possible trans-organ actions under metabolic disturbance.
methodsPubMed, Web of Science, Scopus, and CNKI were searched from January 2000 to September 2025. Original in vivo or in vitro studies were included when a defined MFH-derived constituent or standardized single-material extract was tested in an osteoporosis-relevant model and reported both bone-related and metabolism-related outcomes.
resultsA total of 38 bioactive components from 24 MFH materials were identified and regrouped into seven higher-level natural-product categories, including flavonoids, phenolic and polyphenolic compounds, polysaccharides, saponins, terpenoids, proteins/peptides, and other specialized metabolites. Across studies, osteoprotective effects were frequently accompanied by parallel improvements in lipid metabolism, inflammatory status, oxidative stress, gut microbiota, or related metabolites. These findings suggest that MFH bioactives may act beyond bone-local signaling alone. In the discussion, this pattern was further interpreted through liver-bone and gut-bone.
conclusionMFH-derived bioactives show potential to improve osteoporosis-related phenotypes and may exert broader systemic regulatory effects, although specific mediators and causal links still require validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.